IL2 and rheumatoid arthritis: Low-dose IL2 therapy increased Th17 cells slightly while a significant increase in Treg cells was seen along with other peripheral blood lymphocytes. This increase was correlated with relieving patients' clinical symptoms without expected adverse effects. Hence low-dose IL2 therapy can induce remission of RA disease activity rapidly in refractory RA patients.